HIV 1 News and Research

RSS

Study demonstrates how pan-sarbecovirus ORF7a protein plays a role in evading host immunity

In a new study, researchers demonstrated how sarbecovirus family down-regulates major histocompatibility complex-I (MHC-I) surface expression to evade cellular immunity.

26 Sep 2022

Synthetic mucin gels against HIV-1 and HSV-2 transmission

In a new study, researchers assessed the effectiveness of synthetic mucin gels in the inhibition of human immunodeficiency virus-1 (HIV-1) and herpes simplex virus-2 (HSV-2) Transmission.

21 Sep 2022

Monkeypox infection in a smallpox-vaccinated patient

In a recent study published in the Emerging Infectious Diseases journal, researchers at Madigan Army Medical Center assessed the characteristics of monkeypox infection in a patient vaccinated against smallpox.

20 Sep 2022

Monkeypox virus infection in an immunocompromised patient

Researchers assessed the manifestations of the monkeypox infection in an immunocompromised patient.

19 Sep 2022

BU researcher awarded $7.2 million grant to develop mAb-based contraceptive products

Deborah Jean Anderson, PhD, professor of medicine at Boston University School of Medicine, has received a four-year, $7.2 million grant from the NIH's National Institute of Child Health and Human Development renewing support for a Contraceptive Research Center at BUSM to further her research to develop innovative monoclonal antibody (mAb)-based contraceptive and multipurpose prevention technology (MPT) products.

15 Sep 2022

Dolutegravir-based regimen more effective for treating pregnant people with HIV-1

Dolutegravir-based antiretroviral therapies (ART) for HIV-1 are more effective for pregnant people than some other ART regimens commonly used in the U.S. and Europe, according to a study led by Harvard T.H. Chan School of Public Health researchers.

1 Sep 2022

Novel mechanism identified that SARS-CoV-2 uses to suppress antiviral responses to make the cell more permissive to infection

Researchers assessed the impact of SARS-CoV-2 ORF-6 on innate immune signaling.

30 Aug 2022

How natural alterations inside the SARS-CoV-2 glycan barrier affect spike protein dynamics

Researchers explored how the natural alterations inside the SARS-CoV-2 glycan barrier affect the spike protein dynamics.

22 Aug 2022

Impact of SARS-CoV-2 Omicron subvariant breakthrough infections on memory responses

Researchers examined antibodies (Abs) generated by memory B cells (MBCs) after three and four SARS-CoV-2 exposures by infections with SARS-CoV-2 Delta and Omicron BA.1 variants, respectively.

16 Aug 2022

How does the interval between the 1st and 2nd BNT162b2 doses impact the neutralization breadth and potency against variants of concern?

Scientists explored the influence of SARS-CoV-2 extended gap vaccination on the variants of concern neutralization.

9 Aug 2022

mRNA vaccines induce faster antibody response against infectious diseases

A new study describes that mRNA vaccines induce antigen-specific antibody response within a very short period of time after immunization.

2 Aug 2022

Study investigates the combined effects of aging and HIV-1 Tat expression in mice

A new research paper was published in Aging ("Aging (Albany NY)" by Medline/PubMed, "Aging-US" by Web of Science) Volume 14, Issue 13, entitled, "Age-related neuroendocrine, cognitive, and behavioral co-morbidities are promoted by HIV-1 Tat expression in male mice."

29 Jul 2022

Increased resistance to human interferons could be a potential driver of SARS-CoV-2 evolution

Researchers compared the potency of 17 human interferons (IFNs) against multiple SARS-CoV-2 variants.

27 Jul 2022

Scientists investigate how interferons interact with SARS-CoV-2 variants

Researchers at the University of Colorado Anschutz Medical Campus have investigated how antiviral proteins called interferons interact with SARS-CoV-2, the cause of COVID-19.

25 Jul 2022

Combinations of broadly neutralizing antibodies may be a more effective approach to treat HIV

Carefully designed cocktails of broadly neutralizing antibodies (bNAbs) could help treat HIV while minimizing the risk of the virus escaping treatment, suggests a study published today in eLife.

20 Jul 2022

Scientists uncover how the innate immune system detects and fights HIV-1

Human immunodeficiency virus 1, more commonly known as HIV-1, is known for its uncanny ability to evade the immune system.

8 Jul 2022

Knowledge of HIV Pol polyprotein's structure could spur the development of new therapies

In a discovery that could spur the development of new therapies for more than 40 million HIV patients worldwide, scientists from Rutgers University and the Salk Institute determined the molecular structure of the HIV Pol polyprotein, a protein that plays a critical role in helping the virus propagate itself and spread throughout the body.

7 Jul 2022

Crystal structure of a human endogenous reverse transcriptase revealed

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and other diseases, according to a study co-authored by a Rutgers researcher.

30 Jun 2022

Potent antibody with a novel neutralization mechanism against SARS-CoV-2 variants

In a recent study posted to the bioRxiv* pre-print server, researchers in the United States described a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) SP1-77 that broadly neutralized its multiple variants of concern (VOCs).

28 Jun 2022

Study shows molecular details of HIV-1 assembly and viral envelope protein incorporation

Assembly of HIV-1, which causes AIDS, takes place on the inner plasma membrane leaflet of infected cells, a geometric building process that creates hexamers out of trimers of the viral Gag protein, as guided by Gag's N-terminal matrix domain.

21 Jun 2022